AbCellera Biologics Inc.
ABCL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $8,955 | $17,084 | $4,235 | $5,050 |
| % Growth | -47.6% | 303.4% | -16.1% | – |
| Cost of Goods Sold | $0 | $7,059 | $0 | $0 |
| Gross Profit | $8,955 | $10,025 | $4,235 | $5,050 |
| % Margin | 100% | 58.7% | 100% | 100% |
| R&D Expenses | $55,028 | $39,213 | $42,496 | $46,076 |
| G&A Expenses | $22,052 | $18,977 | $16,226 | $16,020 |
| SG&A Expenses | $24,958 | $21,986 | $19,068 | $19,164 |
| Sales & Mktg Exp. | $2,906 | $3,009 | $2,842 | $3,144 |
| Other Operating Expenses | $5,247 | -$1,589 | $5,331 | $12,565 |
| Operating Expenses | $85,233 | $59,610 | $66,895 | $77,805 |
| Operating Income | -$76,278 | -$49,585 | -$62,660 | -$72,755 |
| % Margin | -851.8% | -290.2% | -1,479.6% | -1,440.7% |
| Other Income/Exp. Net | $30,808 | $13,241 | $9,676 | $25,926 |
| Pre-Tax Income | -$45,470 | -$36,344 | -$52,984 | -$46,829 |
| Tax Expense | $11,649 | -$1,617 | -$7,363 | -$12,619 |
| Net Income | -$57,119 | -$34,727 | -$45,621 | -$34,210 |
| % Margin | -637.8% | -203.3% | -1,077.2% | -677.4% |
| EPS | -0.19 | -0.12 | -0.15 | -0.12 |
| % Growth | -58.3% | 20% | -25% | – |
| EPS Diluted | -0.19 | -0.12 | -0.15 | -0.12 |
| Weighted Avg Shares Out | 298,875 | 298,509 | 297,693 | 294,590 |
| Weighted Avg Shares Out Dil | 298,875 | 298,509 | 297,693 | 294,590 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6,765 | $7,592 | $8,051 | $8,668 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $5,246 | $7,060 | $6,605 | $13,900 |
| EBITDA | -$40,224 | -$38,833 | -$51,902 | -$55,311 |
| % Margin | -449.2% | -227.3% | -1,225.5% | -1,095.3% |